-
March 08, 2024
Handok-Genexine’s long-acting growth hormone gets orphan drug status in Korea
South Korean pharmaceutical company Handok announced Friday that GX-H9, a long-acting recombinant human growth hormone it co-developed with Genexine, has won orphan drug designation from the country's Ministry of Food and Drug Safety. Handok said the designation for GX-H9, which it recei...
-
January 29, 2024
Genexine seeks approval for anemia treatment in Korea
Korean biotech firm Genexine announced Friday that the company has submitted a biologics license application to the country's Ministry of Food and Drug Safety for the company’s anemia treatment Efesa... percent. An equivalent safety performance was also confirmed compared to Mircera, acc...
-
February 22, 2021
US-based NeoImmuneTech eyes W96b IPO in Korea
..., 2021. Hana Financial investment and Mirae Asset Daewoo are underwriting the deal. Based in Rockville, Maryland, the firm was established in 2014 as a spinoff of Korea-based new drug developer Genexine. Genexine is the largest shareholder of NeoImmuneTech, owning a 25.31 pe...
-
June 01, 2020
SCM Lifescience lowers IPO price in second attempt
...n submit a clinical test plan to the Ministry of Food and Drug Safety, according to Rhee. SCM Lifescience jointly set up Colmmune, a cell therapy firm in the US, with another local biotech firm Genexine in February last year. While the two parent companies invested 12.5 billion won to...
-
September 27, 2019
Genexine establishes JV in Thailand
South Korean biotech firm Genexine announced on Sept. 27 that it has signed a contract with the Thai company KinGen Holdings to establish a 50:50 joint venture named KinGen Biotech. KinGen Holdings ... a Thai consortium that is backed by the government, schools and divers investors, acco...
-
August 20, 2019
Genexine, ToolGen cancel merger plan on shareholder opposition
South Korean biopharmaceutical drugmaker Genexine and gene-editing company ToolGen said Aug. 20 in respective regulatory filings that they had dropped plans for a 1:1.2 merger to create ToolGenex...value. For shareholders, the appraisal rights could be executed in exchange for 67,325...
-
April 16, 2019
NeoImmuneTech’s drug candidate obtains US FDA orphan drug designation
...proliferation and that helps the body fight serious disease, was co-developed by Korean company Genexine and Maryland-based NeoImmuneTech. The FDA grants orphan status to drugs that are intended for ...s Agency. Established in 2014, NeoImmuneTech is a spun-off entity of Korean new dru...
-
February 13, 2019
Genexine, SCM acquire US biotech firm for W12.5b
Korean firms Genexine and SCM Life science announced on Feb. 13 that they have jointly acquired US biotech firm Argos Therapeutics for around 12.5 billion won (US$ 11.14 million) through an auction...atients in the US and other countries. It also has facilities to develop advanced medic...
-
January 08, 2019
Handok Pharma, Genexine purchase US bio firm
[THE INVESTOR] Korean firm Handok Pharmaceuticals said on Jan. 8 that it has entered a US$25 million preferred stock purchase agreement with local player Genexine to invest in an American drug maker. The arrangement allows the two companies to purchase a combined 54 percent share of ...